Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Biomarcadores; Células tumorales circulantes; Docetaxel

Bibliographic Details
Authors: Lozano, Rebeca, Lorente, David, Aragon, Isabel M., Romero-Laorden, Nuria, Nombela, Paz, Mateo Valderrama, Joaquim
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/7102
Online Access:https://hdl.handle.net/11351/7102
http://hdl.handle.net/11351/7102
Access Level:Open access
Keyword:Pròstata - Càncer - Tractament
Cèl·lules canceroses - Proliferació
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, Circulating
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica::células neoplásicas circulantes
id ES_e5a32975e14bb3a2b4431ead79caeff8
oai_identifier_str oai:recercat.cat:11351/7102
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
title Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
spellingShingle Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Lozano, Rebeca
Pròstata - Càncer - Tractament
Cèl·lules canceroses - Proliferació
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, Circulating
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica::células neoplásicas circulantes
title_short Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
title_full Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
title_fullStr Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
title_full_unstemmed Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
title_sort Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
dc.creator.none.fl_str_mv Lozano, Rebeca
Lorente, David
Aragon, Isabel M.
Romero-Laorden, Nuria
Nombela, Paz
Mateo Valderrama, Joaquim
author Lozano, Rebeca
author_facet Lozano, Rebeca
Lorente, David
Aragon, Isabel M.
Romero-Laorden, Nuria
Nombela, Paz
Mateo Valderrama, Joaquim
author_role author
author2 Lorente, David
Aragon, Isabel M.
Romero-Laorden, Nuria
Nombela, Paz
Mateo Valderrama, Joaquim
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Lozano R, Aragon IM] Genitourinary Cancer Traslational Research Group, The Institute of Biomedical Research in Málaga (IBIMA), 29010 Málaga, Spain. Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Lorente D] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Servicio de Oncología Médica, Hospital Provincial de Castellón, 12004 Castellón de la Plana, Spain. [Romero-Laorden N] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Hospital Universitario La Princesa, 28006 Madrid, Spain. [Nombela P] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Mateo J] The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, Sutton, London SM2 5PT, UK. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Pròstata - Càncer - Tractament
Cèl·lules canceroses - Proliferació
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, Circulating
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica::células neoplásicas circulantes
topic Pròstata - Càncer - Tractament
Cèl·lules canceroses - Proliferació
Metàstasi
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, Circulating
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica::células neoplásicas circulantes
description Biomarcadores; Células tumorales circulantes; Docetaxel
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/7102
http://hdl.handle.net/11351/7102
url https://hdl.handle.net/11351/7102
http://hdl.handle.net/11351/7102
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Cancers;13(10)
https://doi.org/10.3390/cancers13102334
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422696707653632
spelling Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsLozano, RebecaLorente, DavidAragon, Isabel M.Romero-Laorden, NuriaNombela, PazMateo Valderrama, JoaquimPròstata - Càncer - TractamentCèl·lules canceroses - ProliferacióMetàstasiDISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-ResistantOther subheadings::Other subheadings::Other subheadings::/drug therapyDISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis::Neoplastic Cells, CirculatingENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castraciónOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica::células neoplásicas circulantesBiomarcadores; Células tumorales circulantes; DocetaxelBiomarkers; Circulating tumor cells; DocetaxelBiomarcadors; Cèl·lules tumorals circulants; DocetaxelCirculating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3–6 weeks post treatment initiation. Cox regression models were constructed to compare 6-month radiographical progression-free survival (rPFS), CTCs and PSA changes predicting outcome. Among the subjects, 80 and 52 patients had evaluable baseline and post-treatment CTC counts, respectively. A significant association of higher baseline CTC count with worse overall survival (OS), PFS and time to PSA progression (TTPP) was observed. While CTC response at 3–6 weeks (CTC conversion (from ≥5 to <5 CTCs), CTC30 (≥30% decline in CTC) or CTC0 (decline to 0 CTC)) and 6-month rPFS were significantly associated with OS (all p < 0.005), the association was not significant for PSA30 or PSA50 response. CTC and PSA response were discordant in over 50% of cases, with outcome driven by CTC response in these patients. The c-index values for OS were superior for early CTC changes compared to PSA response endpoints, and similar to 6-month rPFS. Early CTC declines were good predictors of improved outcomes in mCRPC patients treated with docetaxel in this small study, offering a superior and/or earlier estimation of docetaxel benefit in comparison to PSA or rPFS that merits further confirmation in larger studies.The results reported here were generated as part of two academic studies supported by various grants. The funding sources had no role in study design, data analysis, data interpretation or writing of the report. R.L., D.L. and D.O. had full access to all of the data and had final responsibility for the decision to submit for publication. This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.MDPIInstitut Català de la Salut[Lozano R, Aragon IM] Genitourinary Cancer Traslational Research Group, The Institute of Biomedical Research in Málaga (IBIMA), 29010 Málaga, Spain. Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Lorente D] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Servicio de Oncología Médica, Hospital Provincial de Castellón, 12004 Castellón de la Plana, Spain. [Romero-Laorden N] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Hospital Universitario La Princesa, 28006 Madrid, Spain. [Nombela P] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Mateo J] The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, Sutton, London SM2 5PT, UK. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/7102http://hdl.handle.net/11351/7102Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCancers;13(10)https://doi.org/10.3390/cancers13102334Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/71022026-05-29T05:05:01Z
score 15,812429

Similar Items